Pharmacokinetics and Pharmacodynamics: Introduction

Pharmacokinetics fundamentals explore how drugs move through the body via absorption, distribution, metabolism, and elimination processes. This JoVE Coach course covers essential PK PD drug principles, mathematical modeling, dose-response relationships, and regulatory frameworks governing pharmaceutical development in the United States healthcare system.

• Understand the four fundamental pharmacokinetic processes: absorption, distribution, metabolism, and elimination
• Learn to interpret drug concentration-time curves and calculate key parameters like Cmax, Tmax, and AUC
• Identify different pharmacokinetic models including compartmental, empirical, and physiological approaches
• Explore mathematical principles underlying drug kinetics, including zero-order and first-order reactions
• Analyze dose-response relationships and distinguish between drug agonism and antagonism
• Apply structure-activity relationship concepts to predict drug efficacy and safety profiles
• Understand population pharmacokinetics and inter-individual variability in drug responses
• Learn regulatory frameworks governing drug approval and control in the United States

1. Fundamental Pharmacokinetic Processes The body processes drugs through four distinct phases: absorption (drug entry into bloodstream), distribution (movement to target tissues), metabolism (chemical transformation), and elimination (removal from body). These processes determine drug effectiveness and safety. For example, oral medications like acetaminophen must first dissolve in gastric fluids, absorb through intestinal walls, distribute via circulation to liver tissues, undergo hepatic metabolism, and eliminate through kidneys. Understanding these processes helps healthcare providers optimize dosing regimens for conditions like hypertension or diabetes management.

2. Drug Concentration-Time Relationships Plasma drug concentration measurements reveal critical pharmacokinetic parameters essential for therapeutic monitoring. Key metrics include Cmax (peak concentration), Tmax (time to peak), and AUC (area under curve representing total drug exposure). The therapeutic window lies between minimum effective concentration (MEC) and minimum toxic concentration (MTC). For instance, digoxin used in heart failure requires careful monitoring since its narrow therapeutic window means concentrations slightly above 2.0 ng/mL can cause dangerous arrhythmias, while levels below 0.8 ng/mL provide insufficient therapeutic benefit.

3. Pharmacokinetic Modeling Approaches Mathematical models predict drug behavior using compartmental, empirical, or physiological approaches. Compartmental models treat the body as interconnected compartments with uniform drug distribution. The central compartment represents plasma and highly perfused organs like heart and liver, while peripheral compartments represent less perfused tissues like muscle and fat. Physiological models incorporate actual organ sizes and blood flow rates. For example, modeling chemotherapy drug distribution helps oncologists at institutions like MD Anderson Cancer Center optimize dosing protocols for different cancer types.

4. Mathematical Principles in Drug Kinetics Pharmacokinetic analysis relies heavily on calculus and mathematical modeling. Zero-order kinetics describe constant elimination rates regardless of drug concentration, exemplified by alcohol metabolism at approximately 15 mg/dL per hour. First-order kinetics show elimination rates proportional to drug concentration, typical for most medications like antibiotics and analgesics. Linear regression analysis of log concentration versus time plots determines elimination rate constants. These mathematical relationships enable precise dosing calculations for medications ranging from insulin therapy to chemotherapy protocols used in American hospitals.

5. Pharmacodynamics and Drug-Receptor Interactions Pharmacodynamics examines how drugs produce biological effects through receptor binding and cellular responses. Drug affinity measures binding strength, while efficacy indicates maximum achievable effect. Agonists activate receptors triggering responses, while antagonists block receptors preventing responses. For example, morphine acts as an opioid receptor agonist providing pain relief, while naloxone serves as an antagonist reversing opioid overdoses. Understanding these interactions guides medication selection for conditions like depression, where selective serotonin reuptake inhibitors demonstrate high receptor specificity compared to older tricyclic antidepressants.

6. Structure-Activity Relationships and Drug Design Chemical structure directly influences drug activity through structure-activity relationships (SAR). Molecular modifications alter affinity, potency, and selectivity. Beta-blocker development illustrates SAR principles: first-generation agents like propranolol blocked both β1 and β2 receptors causing side effects including bronchospasm. Subsequent SAR analysis led to selective β1 blockers like metoprolol, reducing respiratory complications while maintaining cardiovascular benefits. American pharmaceutical companies like Pfizer and Merck extensively utilize SAR principles during drug discovery phases, optimizing lead compounds for improved therapeutic profiles.

7. Regulatory Framework and Drug Control The FDA regulates pharmaceutical development, approval, and marketing in the United States through rigorous clinical trial requirements and post-market surveillance. Drug scheduling classifies controlled substances based on abuse potential and medical utility, from Schedule I (high abuse potential, no medical use) to Schedule V (low abuse potential, accepted medical use). For example, morphine (Schedule II) requires special prescribing protocols, while codeine combinations (Schedule III) have less restrictive requirements. Recent FDA approvals like COVID-19 vaccines and novel cancer therapies demonstrate the agency's role in protecting American public health.